文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

骨肉瘤与转移

Osteosarcoma and Metastasis.

作者信息

Sheng Gaohong, Gao Yuan, Yang Yong, Wu Hua

机构信息

Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出版信息

Front Oncol. 2021 Dec 10;11:780264. doi: 10.3389/fonc.2021.780264. eCollection 2021.


DOI:10.3389/fonc.2021.780264
PMID:34956899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8702962/
Abstract

Osteosarcoma is the most common primary bone malignancy in adolescents. Its high propensity to metastasize is the leading cause for treatment failure and poor prognosis. Although the research of osteosarcoma has greatly expanded in the past decades, the knowledge and new therapy strategies targeting metastatic progression remain sparse. The prognosis of patients with metastasis is still unsatisfactory. There is resonating urgency for a thorough and deeper understanding of molecular mechanisms underlying osteosarcoma to develop innovative therapies targeting metastasis. Toward the goal of elaborating the characteristics and biological behavior of metastatic osteosarcoma, it is essential to combine the diverse investigations that are performed at molecular, cellular, and animal levels from basic research to clinical translation spanning chemical, physical sciences, and biology. This review focuses on the metastatic process, regulatory networks involving key molecules and signaling pathways, the role of microenvironment, osteoclast, angiogenesis, metabolism, immunity, and noncoding RNAs in osteosarcoma metastasis. The aim of this review is to provide an overview of current research advances, with the hope to discovery druggable targets and promising therapy strategies for osteosarcoma metastasis and thus to overcome this clinical impasse.

摘要

骨肉瘤是青少年中最常见的原发性骨恶性肿瘤。其高转移倾向是治疗失败和预后不良的主要原因。尽管在过去几十年中骨肉瘤的研究有了很大进展,但针对转移进展的知识和新治疗策略仍然匮乏。发生转移的患者预后仍然不尽人意。迫切需要深入透彻地了解骨肉瘤的分子机制,以开发针对转移的创新疗法。为了阐述转移性骨肉瘤的特征和生物学行为,有必要将从基础研究到临床转化、跨越化学、物理科学和生物学等多个领域、在分子、细胞和动物水平上进行的各种研究结合起来。本综述重点关注骨肉瘤转移过程、涉及关键分子和信号通路的调控网络、微环境、破骨细胞、血管生成、代谢、免疫以及非编码RNA在骨肉瘤转移中的作用。本综述旨在概述当前的研究进展,希望能发现可成药靶点以及有前景的骨肉瘤转移治疗策略,从而克服这一临床难题。

相似文献

[1]
Osteosarcoma and Metastasis.

Front Oncol. 2021-12-10

[2]
Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.

Front Oncol. 2020-1-31

[3]
The interaction between osteosarcoma and other cells in the bone microenvironment: From mechanism to clinical applications.

Front Cell Dev Biol. 2023-5-3

[4]
MicroRNAs in osteosarcoma: from biological players to clinical contributors, a review.

J Int Med Res. 2013-2

[5]
New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?

Int J Mol Sci. 2019-7-31

[6]
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.

Cancer Lett. 2021-3-1

[7]
Bone Microenvironment and Osteosarcoma Metastasis.

Int J Mol Sci. 2020-9-23

[8]
Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis.

Cancers (Basel). 2023-10-23

[9]
Noncoding RNAs in osteosarcoma: Implications for drug resistance.

Cancer Lett. 2021-4-28

[10]
Role of ezrin in osteosarcoma metastasis.

Adv Exp Med Biol. 2014

引用本文的文献

[1]
Molecular and Glycosylation Pathways in Osteosarcoma: Tumor Microenvironment and Emerging Strategies Toward Personalized Oncology.

Curr Issues Mol Biol. 2025-8-7

[2]
Molecular Crosstalk Between RUNX2 and HIF-1α in Osteosarcoma: Implications for Angiogenesis, Metastasis, and Therapy Resistance.

Int J Mol Sci. 2025-8-7

[3]
Cluster of differentiation 133 (CD133) and C-X-C chemokine receptor 4 (CXCR4) associated with the incidence of metastasis in osteosarcoma patients.

Eur J Orthop Surg Traumatol. 2025-7-23

[4]
Development and validation of a predictive score for chemoresistance in high-grade osteosarcoma at baseline.

Front Med (Lausanne). 2025-7-4

[5]
Systemic strategies for osteosarcoma: advances and future directions.

Discov Oncol. 2025-7-18

[6]
Urolithin A suppressed osteosarcoma cell migration and invasion via targeting MMPs and AKT1.

Sci Rep. 2025-7-17

[7]
Whole‑exome evolutionary profiling of osteosarcoma uncovers metastasis‑related driver mutations and generates an independently validated predictive classifier.

J Transl Med. 2025-7-7

[8]
Comparison of Differentially Expressed Genes in Human and Canine Osteosarcoma.

Life (Basel). 2025-6-12

[9]
Osteosarcoma: current insights and advances.

Explor Target Antitumor Ther. 2025-6-15

[10]
Silencing of AEBP1 inhibits proliferation and promotes apoptosis via the AKT signaling pathway in osteosarcoma.

Biomed Rep. 2025-5-30

本文引用的文献

[1]
miRNA-221-3p derived from M2-polarized tumor-associated macrophage exosomes aggravates the growth and metastasis of osteosarcoma through SOCS3/JAK2/STAT3 axis.

Aging (Albany NY). 2021-8-13

[2]
Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.

Cell Prolif. 2021-9

[3]
Osteosarcoma and Metastasis Associated Bone Degradation-A Tale of Osteoclast and Malignant Cell Cooperativity.

Int J Mol Sci. 2021-6-25

[4]
The Effect of Fluid Flow Shear Stress and Substrate Stiffness on Yes-Associated Protein (YAP) Activity and Osteogenesis in Murine Osteosarcoma Cells.

Cancers (Basel). 2021-6-23

[5]
Osteosarcoma-Derived Small Extracellular Vesicles Enhance Tumor Metastasis and Suppress Osteoclastogenesis by miR-146a-5p.

Front Oncol. 2021-5-4

[6]
Macrophages-derived exosomal lncRNA LIFR-AS1 promotes osteosarcoma cell progression via miR-29a/NFIA axis.

Cancer Cell Int. 2021-4-1

[7]
Plasma Exosome-Derived Sentrin SUMO-Specific Protease 1: A Prognostic Biomarker in Patients With Osteosarcoma.

Front Oncol. 2021-3-9

[8]
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.

Cancer Lett. 2021-3-1

[9]
LncRNA CASC15 is Upregulated in Osteosarcoma Plasma Exosomes and CASC15 Knockdown Inhibits Osteosarcoma Progression by Regulating miR-338-3p/RAB14 Axis.

Onco Targets Ther. 2020-11-23

[10]
Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis.

Sci Rep. 2020-11-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索